{"date":"2025-01-22","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4174-2025-01-22-1529-2jmiw7","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-01-22","time":"15:29:11","subject":"代重要子公司鼎晉生技公告，OBI-858新型肉毒桿菌素獲台灣衛福部食藥署核准進行「重複劑量安全性二期臨床試驗」","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-01-22 15:29，「代重要子公司鼎晉生技公告，OBI-858新型肉毒桿菌素獲台灣衛福部食藥署核准進行「重複劑量安全性二期臨床試驗」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}